Working... Menu
Trial record 6 of 20 for:    Irofulven

Study of Irofulven in Combination With Oxaliplatin in Patients With Advanced Solid Tumors

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details. Identifier: NCT00374660
Recruitment Status : Unknown
Verified June 2015 by Eisai Inc..
Recruitment status was:  Active, not recruiting
First Posted : September 11, 2006
Last Update Posted : July 1, 2015
Information provided by (Responsible Party):
Eisai Inc.

Brief Summary:
The purpose of this study is to determine the maximum tolerated dose (MTD) and to investigate the efficacy, safety and pharmacokinetics of irofulven combined with oxaliplatin in patients with advanced solid tumors.

Condition or disease Intervention/treatment Phase
Liver Cancer Drug: Irofulven + oxaliplatin Phase 1 Phase 2

Layout table for study information
Study Type : Interventional  (Clinical Trial)
Actual Enrollment : 63 participants
Allocation: Non-Randomized
Intervention Model: Single Group Assignment
Masking: None (Open Label)
Primary Purpose: Treatment
Official Title: Phase I-II Clinical and Pharmacokinetic Study of Irofulven in Combination With Oxaliplatin in Patients With Advanced Solid Tumors
Study Start Date : June 2003
Actual Primary Completion Date : August 2007

Resource links provided by the National Library of Medicine

MedlinePlus related topics: Liver Cancer
Drug Information available for: Oxaliplatin

Arm Intervention/treatment
Experimental: 1 Drug: Irofulven + oxaliplatin

Oxaliplatin will be administered in a 2-hour infusion on Days 1 and 15 of a 28-day cycle. Starting dose 40 mg/m^2, dose escalation 50, 60, 70, and 80 mg/m^2 every 28 days if no dose-limiting toxicity.

Thirty minutes after completion of oxaliplatin infusion, irofulven will be administered in a 30-minute infusion on Days 1 and 15 of a 28-day cycle. Starting dose 0.30 mg/kg, dose escalation to 0.40 mg/kg every 28 days if no dose-limiting toxicity.

Primary Outcome Measures :
  1. Confirmed response rate: Hepatocellular Cancer (HCC) Cohort: Response Evaluation Criteria in Solid Tumors (RECIST) criteria. [ Time Frame: Every 8 weeks until progression. ]
  2. Hormone Refractory Prostate Cancer (HRPC) Cohort: Prostate-Specific Antigen Working Group Recommendations (PSAWGR) and RECIST criteria. [ Time Frame: Every 8 weeks until progression. ]

Secondary Outcome Measures :
  1. Efficacy: HRPC Cohort: confirmed response rate according to RECIST; progression-free survival (PFS) for progression according to RECIST; new bone lesions or skeletal events; PFS according to PSA progression; overall survival. [ Time Frame: Every 8 weeks until progression. ]
  2. Efficacy: HCC cohort - PFS (RECIST); overall survival [ Time Frame: Every 8 weeks until progression. ]

Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.

Layout table for eligibility information
Ages Eligible for Study:   18 Years and older   (Adult, Older Adult)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No

Inclusion Criteria:

  1. Signed informed consent obtained prior to initiation of any study-specific procedures and treatment.
  2. Malignant solid tumor confirmed by a biopsy sample.
  3. Pancreatic, endometrial, gastric, and hepatocellular cancer patients that have exhausted standard treatment options.
  4. Measurable disease according to RECIST.
  5. 18 years of age or older.
  6. Eastern Cooperative Oncology Group (ECOG) Performance Status (PS): 0-1.
  7. Life expectancy greater than 3 months.
  8. Previous anticancer treatment must be discontinued at least 4 weeks prior to first dose of study treatment (6 weeks for mitomycin C, 8 weeks for bicalutamide).
  9. Patients of reproductive age must be using effective contraceptive methods.
  10. Negative pregnancy test for patients of reproductive potential.

Exclusion Criteria:

  1. Prior therapy with irofulven or oxaliplatin.
  2. Patients who have had radiation therapy to more than 30% of the bone marrow prior to entry into the study.
  3. Prior chemotherapy with nitrosoureas or high dose carboplatin (AUC > 6), prior mitomycin C cumulative dose greater than or equal to 25 mg/m², prior bone marrow transplant or intensive chemotherapy with stem cell support.
  4. Presence of any serious concomitant systemic disorders incompatible with the study (e.g., uncontrolled congestive heart failure, active infection).
  5. Any previous history of another malignancy (other than cured basal cell carcinoma of the skin or cured in-situ carcinoma of the cervix) within 5 years of study entry, unless the active malignancy can be unmistakably identified by evidence such as recent biopsies or tumor specific markers.
  6. Treatment with any other investigational agent, or participation in another clinical trial within 28 days prior to study entry.
  7. Pregnant or lactating patients or any patient with childbearing potential not using adequate contraception.
  8. Patients with retinopathy or significant visual impairment not correctable by refractory lens will be enrolled on a case by case basis according to the expected benefit ratio, taking into account the malignant disease and the existence of an objective decreased visual acuity and its degree.

Please note: There are additional criteria that must be met in order to be eligible for this study.

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its identifier (NCT number): NCT00374660

Layout table for location information
Bordeaux, France
Clichy, France
Lyon, France
Nice, France
Paris, France
Poitiers, France
Saint Cloud, France
Sponsors and Collaborators
Eisai Inc.

Layout table for additonal information
Responsible Party: Eisai Inc. Identifier: NCT00374660     History of Changes
Other Study ID Numbers: IROF-017
First Posted: September 11, 2006    Key Record Dates
Last Update Posted: July 1, 2015
Last Verified: June 2015

Keywords provided by Eisai Inc.:

Additional relevant MeSH terms:
Layout table for MeSH terms
Liver Neoplasms
Digestive System Neoplasms
Neoplasms by Site
Digestive System Diseases
Liver Diseases
Antineoplastic Agents
Antineoplastic Agents, Alkylating
Alkylating Agents
Molecular Mechanisms of Pharmacological Action